In 2008, we co-sponsored this MAPS-led trial of LSD-assisted psychotherapy for end-of-life anxiety. This was the first LSD study approved by the U.S. Food and Drug Administration in 40 years, and the results demonstrated that LSD paired with psychotherapy could alleviate ‘existential stress’ associated with terminal illness, putting the drug’s medical potential back in the spotlight for the first time since the 1960s.
Journal of Psychopharmacology, 2015
The Journal of Nervous and Mental Disease, 2014
Psilocybin for Depression
Type of publication